Zhitong Financial APP News, Toujing Life (300642.SZ) announcement The company and its wholly-owned subsidiary Shanghai Tuojing Diagnostic Technology Co., Ltd. ("Tuojing Diagnostics" or "wholly-owned subsidiary") plan to work with Shanghai Maisheng Jingwu Enterprise Management Partnership (Limited Partnership) ("Maisheng Jingwu"), Yao Jianer, Niu Zhengxiang and Zhan Hong with their respective shareholdings of Shanghai Maishi Biotechnology Co., Ltd. ("Maishi Bio"), Wu Liang, a natural person, jointly owns 5.71% of the equity. Among them, the company and Transvision Diagnostics have a total of 861520 yuan of their own capital to transfer Wu Liang to hold 3.46% of the shares of Pulse Biology. After the completion of this transaction, the proportion of shares held by the company and Tuojing Diagnostics increased to 60.61%, which is still a holding subsidiary of the company.
It is reported that pulse biology, as an important part of the company's mass spectrometry analysis business line, focuses on the research, development, production and sales of clinical mass spectrometry-related in vitro diagnostic products, which not only covers clinically well-known items, such as drug concentration testing, neonatal screening, vitamins, nutrients and other conventional products, but also for the cardiovascular field from early risk assessment to late prognosis monitoring layout of a series of characteristic products. Based on the company's long-term strategic development goal in the field of in vitro diagnosis, and good prospects for the future development of mass spectrometry business, the company and Transvision Diagnostics intend to participate in the transfer of minority shareholders' equity according to the corresponding proportion of equity. In order to promote the sustained and stable development of pulse organisms, at the same time help to enhance the management and control of pulse organisms, and further improve the efficiency of decision-making.